Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict brain fog in older women fighting ovarian cancer?

NCT ID NCT07716800

Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study follows women aged 70 and older with ovarian cancer to understand why some experience cognitive decline or delirium during treatment. Researchers will track memory, thinking skills, frailty, and quality of life over 12 months, and analyze blood samples for markers of brain health. The goal is to identify early warning signs and build a risk prediction model to guide personalized care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a way to identify older women with ovarian cancer who are at high risk for cognitive decline or delirium, enabling earlier support and personalized care.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly improve outcomes. The findings may not apply to all patients or lead to a validated risk tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 205 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women aged ≥70 years with ovarian cancer undergoing active treatment will be recruited from the Oncogeriatric Outpatient Clinic of the Palliative Care and Geriatric Oncology Unit. Eligible patients will be referred by the Gynecologic Oncology Unit for pre-treatment geriatric assessment during the pre-admission evaluation, upon request from the Women's Cancer Day Hospital or the Clinical Pharmacology Day Hospital, or following multidisciplinary discussion at the Ovarian Cancer Tumor Board.

Ages

70 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female sex with ovarian cancer. * Age ≥70 years. * Newly diagnosed ovarian cancer (any stage) or first disease recurrence. * Evaluation before initiation of any anticancer treatment or invasive procedure (e.g., primary cytoreductive surgery, neoadjuvant chemotherapy, image-guided biopsy, or exploratory laparoscopy). * Ability to understand and provide written informed consent, or availability of a legally authorized representative to provide consent. Exclusion Criteria: * Age \<70 years. * Refusal or inability to provide written informed consent and absence of a legally authorized representative.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive decline are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction delirium ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive decline Delirium Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.